expected

health

Asia Pacific cannabis market is expected to reach US$ 22,870.6 million by 2027 from US$ 2,318.6 million in 2019

The market is anticipated to grow with a CAGR of 28. 6% from 2020 to 2027. The growth of the Asia Pacific cannabis market is attributed to increasing research on medical cannabis and rising cannabis industry in Southeast Asia.

New York, Nov. 03, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Cannabis Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Product Type ; Application ; Compound, and Country” – https://www.reportlinker.com/p05978820/?utm_source=GNW
However, restriction on the use of cannabis in the region is likely to hinder the market growth during the forecast period.

In recent years, the liberation for the use of cannabis in the medical industry has created various growth opportunities in Southeast Asian countries.Growing legal jurisdictions have enabled the progress of research activities in countries, such as South Korea, Australia, and New Zealand.

Also, various international companies have shown interest in effective market strategies.The companies have strategically enhanced their operational activities by partnering with local players.

For instance, a Canadian market player, Canopy Growth, has expanded its production in South Korea and Thailand.Similarly, MYM Nutraceuticals has expanded its business through its subsidiary MYM Australia.

Such expansions by the companies are expected to drive the cannabis market in the region.

Thailand is among the largest producers of cannabis.In late 2018, it became a cannabis production hub for legalized medical cannabis.

In addition, in December 2018, the military of Thailand voted to legalize medical cannabis use and in February 2019, Thailand legalized medical use of cannabis.Similarly, in January 2019, the Philippine House of Representatives approved the legalization of cannabis in the Philippines.

It has also created a Medical Cannabis Compassionate Center to initiate the creation of a legal cannabis industry.In March 2019, South Korea legalized medical use of cannabis.

Moreover, in March 2019, Japan approved the cannabis compound Epidiolex for clinical trials. Thus, such approvals for cannabis-based products are likely to drive market for cannabis in the Asia Pacific region.
On the other hand, the COVID-19 outbreak is growing in an unexpected way.For instance, according to an article published in May 2020, saying, “The study mentions how they have identified a minimum of 13 cannabis plants that are high in CBD that can affect the ACE2 pathways that the coronavirus uses to get inside one’s body”.

Therefore, it is expected to increase the use of medical cannabis to treat symptoms of COVID-19.

Based on product type, the Asia Pacific cannabis market is segmented into flower, concentrates, and others.In 2019, the flower segment held the largest market share of the cannabis market.

However, the concentrates segment is expected to witness the highest CAGR in the next few years.
In terms of application, the Asia Pacific cannabis market is segmented into medical and recreational.In 2019, the medical segment held larger share of the market.

However, the recreational segment is anticipated to witness fastest growth during the forecast period.

Based on compound, the Asia Pacific cannabis market is segmented into tetrahydrocannabinol (THC)-dominant, cannabidiol (CBD)-dominant, and balanced THC

Read More
health

The Health 202: Obamacare marketplaces survived Trump’s term better than expected

“The overall impact of the Trump administration’s policies towards the marketplaces have probably been more muted than most expected — at least so far,” said Adam Gaffney, a professor at Harvard Medical School and president of Physicians for a National Health Program.

Enrollment in Healthcare.gov and the state-based marketplaces is open through Dec. 15.

People can shop for private plans, and qualify for federal subsidies if their income is between 133 percent and 400 percent of the federal poverty level.

To the concern of health-care advocates, enrollment has ticked down over the past four years, contributing to the nation’s worsening uninsured rate amid the coronavirus pandemic and fueling a growing sense among Democrats that further health restructuring is needed.

Yet by some measures, the marketplaces look healthier than ever.

Individual insurance premiums and choices have steadily improved over the past four years, despite Democrats’ insistence that the administration’s policies would destroy the marketplaces. That trend will continue in the 2021 enrollment season.

“One thing the marketplaces proved is how resilient they actually are,” said Andy Slavitt, former administrator of the Centers for Medicare and Medicaid Services under President Barack Obama.

Still, there’s a clear difference in how a Joe Biden administration would approach the ACA.

It certainly would invest more in boosting marketplace enrollment, advisers say. The Democratic nominee, if he wins tomorrow’s election, is expected to restore funds Trump scrapped to advertise the law and may push Congress to pass legislation increasing the income-based subsidies available to people. 

A Democrat-led administration may also reverse some of the changes President Trump made to the marketplaces — although Trump’s record on them is more nuanced than either party claims.

“The truth is somewhere in middle between what Republicans say and what Democrats say,” said Larry Levitt, a vice president for the Kaiser Family Foundation.

The average Obamacare customer can choose from plans offered by four to five issuers.

That’s up from an average of three to four issuers in 2020, according to data from the Centers for Medicare and Medicaid Services. Four percent of enrollees will have access to plans from just one issuer, up from 12 percent of enrollees this year.

And premiums are declining for the third straight year. The average premiums for the second-lowest-cost “silver”-level plan will be 2 percent lower next year. Average premiums for these “benchmark” plans have declined 8 percent since 2018.

“Despite the uncertainty of the pandemic and concerns about the future of the ACA, the marketplaces are strong and healthy, and premiums for high-quality, comprehensive coverage remain very affordable,” said Joshua Peck, co-founder of Get America Covered — a nonpartisan group that has worked to spread the word about the marketplaces even as the administration has cut advertising for it.

It’s a distinct shift from how things looked during the Obama administration. The first few years of the marketplaces were marked by double-digit premium increases and a steady stream of exits by insurers, as they struggled with how to price and sell insurance

Read More
health

The Asia Pacific liposome drug delivery market is expected to reach US$ 1,562.92 million in 2027 from US$ 759.81 in 2019

The market is estimated to grow with a CAGR of 9. 6% from 2020-2027. The growth of the market is attributed to the some key driving factors such as high incidence of chronic diseases amongst the population, an upsurge in need for non-invasive drug delivery solutions, increasing investments in R&D for pharmaceutical companies.

New York, Oct. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Liposome Drug Delivery Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Product ; Technology ; Application, and Country” – https://www.reportlinker.com/p05978829/?utm_source=GNW
However, high expense involved in the development of drug delivery systems is expected to obstruct the growth of the market to a certain extent during the forecast years.

Liposomes are small sphere-shaped artificial vesicles synthesized from cholesterol and phospholipids. They have multiple layers and a diameter range of 0.01 to 5.0 um. They also have hydrophilic and hydrophobic properties which help liposomes to encapsulate hydrophobic and hydrophilic drugs to be delivered to targeted body site. Liposomes provide an assured system for targeted drug delivery and thereby is the factor influencing the Liposome Drug Delivery market size growth. Liposomes are widely used for enclosing all types of drug molecules such as acyclovir, chloroquine diphosphate, paclitaxel, tropicamide, and cyclosporine. Liposomes are used as a drug carrier for drug therapy for many diseases since they are biodegradable and biocompatible. Also, they have many therapeutic properties like anticancer drugs, genetic materials, proteins, vaccines, macromolecules, and thus can be encapsulated in liposomes.

Research and development (R&D) in liposomal drug delivery systems are increasing across the world due to the increasing prevalence of chronic disease.Drug delivery is the process of dispensing a pharmaceutical compound to attain a therapeutic effect in humans.

Liposomal drug delivery offers multiple advantages such as better pharmacokinetics and pharmacodynamics, enhanced therapeutic efficacy, and decreased toxicity making these delivery systems ideal for patients suffering from various chronic conditions.

Death among the population worldwide has increased due to cancer.The targeted drug delivery system delivers the drug in a controlled manner at a preselected bio site.

Nanotechnology-based delivery systems are making a crucial impact on cancer treatment, and the polymers play a key role in the development of Nano particulate carriers for cancer therapy.Some of the major technological advantages involved in the nanotherapeutic drug delivery systems (NDDS) are prolonged half-life, improved bio-distribution, increased circulation time of the drug, controlled and sustained release of the drug, versatility of route of administration, increased intercellular concentration of the drug, and many more.

The liposomal carriers used in nanotechnology drug delivery systems are likely to experience rapid adoption, which in turn is propelling the market growth.

As per the data provided by, European Society for Medical Oncology, China estimated there were 4.3 million new cancer cases and more than 2.8 million cancer deaths in China in 2015, with lung cancer the most common cancer and the leading cause of cancer death. With high incidences and mortality, cancer is the leading cause of death in China and

Read More
health

The Asia Pacific pulmonary devices market is expected to reach US$ 8,196.82 million by 2027 from US$ 3,661.53 million in 2019

The market is estimated to grow at a CAGR of 10. 6 % during 2019–2027. The growth of the pulmonary devices market in Asia Pacific is attributed to the increasing prevalence of respiratory diseases and growing number of COVID-19 cases.

New York, Oct. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Pulmonary Devices Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Type ; Application ; and End User and country” – https://www.reportlinker.com/p05978832/?utm_source=GNW
Factors such as unfavorable reimbursement scenario associated with the pulmonary device are likely to restrain the growth of the market.

Additionally, strategic activities by manufacturers and increasing preference of home care products are likely to fuel the growth of the pulmonary devices market during the forecast period.

Pulmonary or respiratory devices are used to remove mucus and secretions from the respiratory tract. These medical devices are focused on diagnosis, control, treatment, management, and evaluation of the problems associated with respiratory tract.

The higher prevalence of respiratory disorder is mainly due to the decrease in size of the upper airway lumen in aging population.Millions of people suffer from various respiratory diseases; lung diseases are the most common medical conditions.

Smoking, genetic factors, and infections are among the common factors responsible for respiratory diseases. Medical conditions such as asthma and chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, and lung cancer are among the significant public health burdens.

According to a new Tulane University study published in The Lancet, chronic obstructive pulmonary disease (COPD) is widespread in China with 8.6% of the country’s adult population, i.e. almost 100 million people suffering from the chronic lung disease. Additionally, among India’s 1.31 billion people, about 6% of children and 2% of adults have asthma.

The patients suffering with these respiratory disorders commonly experience difficulty in breathing.Thus, the availability of various pulmonary devices has helped improve the survival rates of the patients suffering from abovementioned medical conditions.

The rising demand for various therapeutic devices among patients with respiratory disorders is expected to augment the growth of the market during the forecast period.

Asia Pacific countries are expected to witness massive challenges due to increasing COVID-19 cases.To manage the COVID-19 outbreak and provide efficient treatment to patients in the region, local medical device companies are ramping up the production of alternative respiratory systems in the Asian countries.

The governments in India and Australia, among others are taking initiative to fulfill the demand of oxygen during COVID-19 pandemic. Thus, the development of these solutions is likely to create a positive impact on market growth in the Asian region.

In 2019, the therapeutic devices segment held the largest share in the market and is expected to retain its dominance till 2027.The multi-modal and multi-functional use of therapeutic devices for a wide range of pulmonary diseases is expected to account for the growth of the therapeutic devices segment over the coming years.

On the other hand, the consumables and accessories segment is expected to witness fastest growth

Read More
health

Fauci says findings on a potential coronavirus vaccine are expected by early December

Dr. Anthony Fauci

“We will know whether a vaccine is safe and effective by the end of November, beginning of December,” the director of the US National Institute of Allergy and Infectious Diseases said. “The amount of doses that will be available in December will not certainly be enough to vaccinate everybody — you’ll have to wait several months into 2021.”

Speaking to the BBC’s Andrew Marr Show, Fauci added that the vaccination of a “substantial proportion of the population” so there could be a “significant impact on the dynamics of the outbreak” may not be possible until the second or third quarter of 2021.

Pence adviser Marty Obst tests positive for coronavirus

“What I do foresee is that with a successful vaccine and the continuation of some form of public health measures, as we go and progress through the months of 2021, getting towards the third and fourth quarter, we will see a considerable approach towards some form of normality,” Fauci told Marr.

Pressed on whether he believes US President Donald Trump is correct in saying that the United States is “rounding the corner” in the course of the pandemic, Fauci said he believes this is untrue.

“The data speak for themselves,” Fauci said.

“Unfortunately, I am sorry to see what I’m viewing from a distance, what I’m seeing in the UK … after getting hit pretty badly the way we did, you went down to a pretty low level, but now you’re starting to escalate in the same manner that we are here,” he added.

Source Article

Read More
medicine

Traditional Chinese Medicine Market Expected to Witness A CAGR Of More than 5% Over the Forecast Period 2020-2030 – Persistence Market Research

NEW YORK, Oct. 23, 2020 /PRNewswire/ — Traditional Chinese medicine is one of the oldest systems of health and wellness that has been used in China for thousands of years. Other medicines mainly focus on treating a disease. But traditional Chinese medicines aim to increase immune power and look at the entire well-being. The most common type of traditional Chinese medicines includes herbal products, acupuncture, and Tai Chi, among others.

According to a latest report published by PMR, the global traditional Chinese medicine marketis expected to witness a CAGR of more than 5% over the forecast period (2020–2030).

Key Takeaways from Traditional Chinese Medicine Market Study  

  • Non-traditional Chinese medicines is the leading segment by product in the global traditional Chinese medicine market. The Autism Spectrum disorder (ASD) segment has been gaining more traction in recent years, and is expected to expand at a rate of 6.7% during the forecast period.
  • North America is the leading region in the traditional Chinese medicine market, followed by Europe.
  • East and South Asia, including China, South Korea, Japan, India, and ASEAN countries, is the fastest-growing region in the traditional Chinese medicine market, due improving medical infrastructure.
  • Tong Ren Tang, Pfizer, and Novartis AG are amongst the leading players in the global traditional Chinese medicine market. These companies invest most of their revenue in R&D, and focus on strengthening their distribution channels to maintain a leading position in the traditional Chinese medicine market space.
  • 100+ health systems are partnering with retail chains, providing physician oversights and increased patient traffic to retail clinics, and extending health system networks to new patient populations.
  • The COVID-19 pandemic is a cause for concern, which has deprioritized non-essential medical treatments. This will hurt the growth of the global traditional Chinese medicine market in the short term

Get PDF Brochure for Research Insights at: https://www.persistencemarketresearch.com/samples/16219

“Increasing incidence of ADHD to boost growth of global traditional Chinese medicine market,” says a PMR analyst.

Rising prevalence of ADHD is a major factor contributing to revenue growth of the traditional Chinese medicine market across the globe. The exact cause of ADHD is still unclear, although genetic influence is observed in most cases.

As per data released by the Centers for Disease Control and Prevention (CDC), approximately 6.1 million (9.4%) – 388,000 children aged 2–5 years, 4 million children aged 6–11 years, and 3 million children aged 12–17 years – were diagnosed with ADHD in the U.S. In Spain, pooled prevalence of ADHD in a population of 361,580 representing children and adolescents was estimated at 6.8% from the last decade.

Get Customization on this Report: https://www.persistencemarketresearch.com/request-customization/16219 

Prevalence of ADHD is rising at an alarming rate, which is expected to fuel revenue growth of ADHD therapeutics such traditional Chinese medicines, as there is no specific treatment for this disorder

Product Innovation – Key Strategy of Traditional Chinese Medicine Market Players

Major players in the global traditional Chinese medicine market are introducing innovative products

Read More
medicine

Traditional Chinese Medicine Market Expected to Witness A CAGR Of More than 5% Over the Forecast Period 2020-2030

NEW YORK, Oct. 23, 2020 /PRNewswire/ — Traditional Chinese medicine is one of the oldest systems of health and wellness that has been used in China for thousands of years. Other medicines mainly focus on treating a disease. But traditional Chinese medicines aim to increase immune power and look at the entire well-being. The most common type of traditional Chinese medicines includes herbal products, acupuncture, and Tai Chi, among others.

Persistence_Market_Research

According to a latest report published by PMR, the global traditional Chinese medicine market
is expected to witness a CAGR of more than 5% over the forecast period (2020-2030).

Key Takeaways from Traditional Chinese Medicine Market Study

  • Non-traditional Chinese medicines is the leading segment by product in the global traditional Chinese medicine market. The Autism Spectrum disorder (ASD) segment has been gaining more traction in recent years, and is expected to expand at a rate of 6.7% during the forecast period.
  • North America is the leading region in the traditional Chinese medicine market, followed by Europe.
  • East and South Asia, including China, South Korea, Japan, India, and ASEAN countries, is the fastest-growing region in the traditional Chinese medicine market, due improving medical infrastructure.
  • Tong Ren Tang, Pfizer, and Novartis AG are amongst the leading players in the global traditional Chinese medicine market. These companies invest most of their revenue in R&D, and focus on strengthening their distribution channels to maintain a leading position in the traditional Chinese medicine market space.
  • 100+ health systems are partnering with retail chains, providing physician oversights and increased patient traffic to retail clinics, and extending health system networks to new patient populations.
  • The COVID-19 pandemic is a cause for concern, which has deprioritized non-essential medical treatments. This will hurt the growth of the global traditional Chinese medicine market in the short term

Get PDF Brochure for Research Insights at: https://www.persistencemarketresearch.com/samples/16219

“Increasing incidence of ADHD to boost growth of global traditional Chinese medicine market,” says a PMR analyst.

Rising prevalence of ADHD is a major factor contributing to revenue growth of the traditional Chinese medicine market across the globe. The exact cause of ADHD is still unclear, although genetic influence is observed in most cases.

As per data released by the Centers for Disease Control and Prevention (CDC), approximately 6.1 million (9.4%) – 388,000 children aged 2-5 years, 4 million children aged 6-11 years, and 3 million children aged 12-17 years – were diagnosed with ADHD in the U.S. In Spain, pooled prevalence of ADHD in a population of 361,580 representing children and adolescents was estimated at 6.8% from the last decade.

Get Customization on this Report: https://www.persistencemarketresearch.com/request-customization/16219

Prevalence of ADHD is rising at an alarming rate, which is expected to fuel revenue growth of ADHD therapeutics such traditional Chinese medicines, as there is no specific treatment for this disorder

Product Innovation – Key Strategy of Traditional Chinese Medicine Market Players

Major players in the global traditional Chinese medicine market are introducing innovative products to retain

Read More
health

The global hospital gowns market is expected to reach US$ 4,542.67 million by 2027 from US$ 2,620.88 million in 2019

The market is estimated to grow with a CAGR of 7. 2% from 2020 to 2027. The growth of the market is attributed to key driving factors, such as increase in number surgical of procedures, initiatives to support health protection of patients from hospital-acquired infections, and key players for hospital gowns focused toward introducing new products.

New York, Oct. 21, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Hospital Gowns Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Type, Risk Type, and Usability, and Geography” – https://www.reportlinker.com/p05978081/?utm_source=GNW
However, adoption of robotic surgeries is expected to obstruct the growth of the market to a certain extent during the forecast period.

There is a rise in number of cardiovascular surgeries and general surgeries performed across the globe.In Europe, the conditions and symptoms such as rise in diabetic cases and lifestyle changes are leading to an increase in number of cardiovascular surgeries and general surgeries.

The incidence of cardiovascular diseases has increased in European countries since the last 25 years.As per the European Cardiovascular Disease Statics, in 2015, about 85 million people in Europe and 49 million in the EU were suffering from cardiovascular diseases.

Along with cardiovascular surgeries, number of general surgeries is also increasing which is expected to fuel the growth of the hospital gowns market during the forecast period.

From the perspective of chronic conditions, cancer and diabetes are the leading causes of mortality across the globe.For instance, as per a study conducted by the American Cancer Society (ACS), in 2018, approximately 1,735,350 new cancer cases were diagnosed in the US.

Furthermore, according to the International Diabetes Federation (IDF), in 2017, an estimated 46 million Americans were suffering from diabetes.This number is expected to reach 62 million by 2045.

The same study also mentioned that ~425 million people worldwide were living with diabetes in 2017 and the number is likely to reach ~629 million by 2045.

Based on type, the hospital gowns market is segmented into surgical gowns, non-surgical gowns, and patient gowns.The surgical gowns segment held the largest share of the market in 2019, and it is anticipated to register the highest CAGR in the market during the forecast period.

Growth of this segment is attributed to rising number of surgeries across the globe, increasing prevalence of chronic diseases, and growing focus on prevention of hospital-acquiredinfections. In addition, continuous innovations by surgical gown manufacturers is further accelerating the growth of the market.
The hospital gowns are among the highly used hospital consumables.Hospitals utilize a large quantity of hospital gowns for the general patients.

Moreover, due to the COVID-19 pandemic, there has been a tremendous rise in the demand for hospital gowns worldwide.Various market players of non-healthcare businesses are engaged in the production of hospital gowns to fulfill the high demand.

The existing players are ramping up the production and supply chain for the hospital gowns.The disposable hospital gowns have become one of the crucial components in the personal protective equipment (PPE) kit that

Read More
health

The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019

The market is estimated to grow with a CAGR of 23. 6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies, and growing technological advancements in metagenomics and next-generation sequencing.

New York, Oct. 20, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Human Microbiome Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product, Disease, Application, and Geography” – https://www.reportlinker.com/p05978083/?utm_source=GNW
On the other hand, strict government guidelines and lack of knowledge and detailed examination are likely to have a negative impact on the growth of the market in the coming years.

Humans usually coexist with the diverse microbial species living within and over humans.Various recent scientific studies have proven that the microbial community essentially acts like an organ of the body that plays a crucial role in human disease management and physiology.

Various basic and translational research efforts have been initiated that focuses on deciphering mechanisms of the microbiome function and the ways that it benefits the human health.Various human medical conditions such as inflammatory bowel diseases and obesity have been closely associated with and are thought to be influenced by the composition of the gut microbial community.

Many efforts are taken to alter the gut microbiome to eradicate several diseases. Probiotics, prebiotics dietary supplements, and foods that contain live microbes have been studied thoroughly to assess their effects on human health.

The Human Microbiome Project of the National Institutes of Health in the US and related international efforts are defining the varieties of a normal microbiome, studying how changes in the microbiota relate to diseases. Large governmental research initiatives including the Human Microbiome Project in the U.S. and the MetaHIT Project in Europe have accelerated research on the human microbiome.

Based on product, the human microbiome market is segmented into probiotics, foods, prebiotics, medical foods, diagnostic devices, drugs, and supplements. In 2019, the probiotics segment held the largest share of 24.73% of the human microbiome market, by product. This segment is also expected to dominate the market in 2027 owing to increasing health concerns; growing awareness regarding the relation of nutrition, diet, and health; and increasing probiotics market penetration in dairy and other foods. Furthermore, the prebiotics segment is anticipated to witness the fastest growth rate during the forecast period.

Several players have observed good demand for human microbiome based products during the initial period of COVID-19, particularly from the food & beverages industry.In addition, researchers are studying the correlation between gut bacteria and COVID-19.

Many researchers have showcased gut bacteria’s implication in different health conditions, from type 2 diabetes to depression. However, the obstacles in supply chains and distribution networks resulting in unavailability of human microbiome based products in various parts of the world are likely to hamper the growth of the market in 2020.

The Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), European Union, Organization for Economic Co-operation and Development,

Read More
health

The global kidney disease market is expected to reach US$ 133,444.71 million by 2027 from US$ 81,128.11 million in 2019

The market is estimated to grow at a CAGR of 6. 5% from 2020 to 2027. High prevalence of chronic diseases leading to kidney diseases, and favorable reimbursement policy for the kidney disease treatments are the major factorsdriving the growth of the kidney disease market.

New York, Oct. 20, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Kidney Disease Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product Type ; End User, and Geography” – https://www.reportlinker.com/p05978086/?utm_source=GNW
However, the undiagnosed cases of kidney diseaseare hindering the growth of the market.
Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide.High blood pressure and diabetes were the two major causes in 75% of kidney failure cases between 2015 and 2017.

Moreover, according to a study published by the National Kidney Foundation in 2020, around 35.0% of the diabetic population above age 20 years would develop chronic kidney disease over the period of time.
As per the data published by the National Kidney Foundation Inc., in 2020, CKD is likely to cause more deaths than prostate cancer or breast cancer. It is an under-recognized emergency health condition among people. 1 in 3 American adults (about 80 million people) is at a risk due to CKD.

According to the estimates given by the Centers of Disease Control and Prevention (CDC) in 2020, 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. In 2015, 30.3 million people in the US had diabetes as per the American Diabetes Association. According to the CDC, in 2014, around 118,000 people in the US started the treatment for end-stage renal disease, and the number of people taking this treatment is expected to increase as more people become aware of this condition. Moreover, the CDC states that around 96% of the people with kidney damage are not aware of having chronic kidney disease, which indicates the underlying market prospective in the kidney disease market. These factors are expected to enhance the market growth during the forecast period.
The global kidney disease market is segmented based onproduct type and end user.Based on product type, the market is segmented into diagnosis and treatment.

The diagnosis segment held the largest share of the market in 2019 and the same segment is anticipated to register the highest CAGR in the market during the forecast period.In terms of enduser, the kidney disease market has been segmented into hospitals, diagnostic laboratories, and others.
Saudi Center for Organ Transplantation,South Australian Health and Medical Research Institute,World Health Organization, Pharmaceuticals and Medical Devices Agency, European Medical Association, World Trade Organization, Pharmaceutical Research and Manufacturers of America, and European Federation of Pharmaceuticals Industries Associations are among the essential secondary sources referred to while preparing this report.
Read the full report: https://www.reportlinker.com/p05978086/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you

Read More